How would you handle recurring toxicity such as cytopenias for patients receiving subcutaneous pertuzumab/trastuzumab?  


Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at Premier Hem and Onc Svcs
Agree with most, I would adjust the chemotherapy d...
Sign in or Register to read more